|
To,
The Members,
TruAlt Bioenergy Limited, (the "Company")
Your Directors have pleasure in presenting the 4th (Fourth) Annual
Report of your Company along with the Audited Financial Statements (Standalone and
Consolidated) for the Financial Year ended on March 31, 2025 ("FY 257or
"financial year under review'Vor "period under review"). Further, in
compliance with the Companies Act, 2013, the Company has made all requisite disclosures in
the Board's Report with the objective of accountability and transparency in its operations
and to make you aware about its performance and future perspective.
1. Financial Results
The Company's financial performance (Standalone and Consolidated) and
highlights for the financial year under review, forming part of this Annual Report, have
been prepared in accordance with the applicable Indian Accounting Standards (AS).
Key highlights of financial performance of the Company for the
financial year under review, as compared to the previous financial year is summarized as
below:
[Amount in Rs. in Lakhs except EPS]
FINANCIAL HIGHLIGHTS
Particulars |
Consolidated |
Consolidated |
Standalone |
Standalone |
|
2024-25 |
2023-24 |
2024-25 |
2023-24 |
| Total Income |
1,96,852.78 |
1,28,018.77 |
1,94,070.60 |
1,27,342.93 |
| Profit/Goss) before Depreciation, Finance
Costs, Exceptional items and Tax Expense (PBIDTA) |
36,994.75 |
24,486.81 |
35,778.32 |
24,409.78 |
| Depreciation/ Amortisation |
(6,689.37) |
(5,691.79) |
(6,459.57) |
(5,578.30) |
| Finance Costs |
(14,361.10) |
(14,307.61) |
(14,103.64) |
(14,101.02) |
| Exceptional items |
- |
- |
- |
- |
Profit/(loss) before Tax Expense |
15,944.28 |
4,487.41 |
15,215.11 |
4,730.46 |
| Tax Expense (Current & Deferred) |
|
|
|
|
| Current |
- |
- |
- |
- |
| Deferred |
(1,280.43) |
(1,306.62) |
(1,153.58) |
(1,269.33) |
Profit /(loss) for the year after Tax |
14,663.85 |
3,180.79 |
14,061.53 |
3,461.13 |
Other comprehensive (loss)/income for the
year |
0.40 |
(8.23) |
0.36 |
(7.77) |
Total Comprehensive Income for the year |
14,664.25 |
3,172.56 |
14,061.89 |
3,453.36 |
| Basic Earnings Per Share (EPS) |
20.94 |
4.25 |
20.08 |
4.71 |
| Diluted Earnings Per Share (EPS) |
20.94 |
4.25 |
20.08 |
4.71 |
Your Directors wish to present the highlights/ the state of Company's
affairs/details of business operations done during the year under review:
Business Overview
Your Company, TruAlt Bioenergy Limited, has continued to strengthen its
position as a leading and diversified player in the Indian bioenergy sector, with a
primary focus on ethanol production. The Company operates five sugarcane
juice/molasses-based distilleries with an aggregate ethanol production capacity of 2,000
kilo litres per day (KLPD), making it the largest ethanol producer in India. During the
year under review, the Company commanded a 7.0% market share in the sugarcane-based
ethanol segment and 3.6% in the overall ethanol market.
To diversify its feedstock base and enhance operational flexibility,
the Company is implementing dual-feed technology with a capacity of 1,300 KLPD to process
surplus and non-edible food grains for ethanol production. Additionally, through its
subsidiary, Leafiniti Bioenergy Private Limited, the Company operates a Compressed Biogas
(CBG) plant under the Government of India's SATAT initiative with a capacity of 10.20
tonnes per day, which also generates solid and liquid fermented organic manure as
by-products.
To scale its CBG operations, Leafiniti has entered into a non-binding
term sheet with GAIL (India) Limited and signed a Memorandum of Understanding (MoU) with
Mitsui & Co. (Asia Pacific) Pte. Ltd. and Osaka Gas Co., Ltd. to jointly establish CBG
plants across India. Further, a non-binding term sheet has been signed with Sumitomo
Corporation Asia & Oceania Pte. Ltd. for collaboration across multiple bioenergy
projects including CBG, Ethanol, and Sustainable Aviation Fuel (SAF).
The Company's strategic roadmap includes the development of up to 24
CBG plants and expansion into high-value segments such as:
¦ First and Second-Generation (2G) Ethanol
¦ Sustainable Aviation Fuel (SAF)
¦ Sugar-derived Biochemicals
¦ Carbon Credit and Decarbonization Initiatives
1. 2G Ethanol Production:
The Company is setting up a 2G ethanol facility utilizing 800,000
metric tonnes of bagasse to produce approximately 60 million litres of ethanol annually. A
Technology Transfer Agreement has been signed with Praj Industries Limited for the
implementation of this advanced technology.
2. Sustainable Aviation Fuel (SAF):
A MoU has been signed with a U.S.-based sustainable fuels technology
company to explore the development of a 100 million litre per annum SAF production
facility using ethanol as feedstock. This aligns with global CORSIA mandates and India's
SAF blending targets.
3. Mevalono Lactone (MVL) & Allied
Biochemicals:
The Company is evaluating the production of MVL through a potential
collaboration with Visolis Inc., USA. Feasibility studies are underway for dual-purpose
fermentation to produce both ethanol and MVL.
4. Biofuel Dispensing Stations:
As part of its forward integration strategy, the Company has commenced
operations of retail biofuel stations in Karnataka offering ethanol blends (E85/E93),
bio-CNG, electric vehicle charging, and non-fuel retail services. The goal is to establish
100 such outlets over the next five years.
Through these strategic initiatives, your Company is evolving into an
integrated and innovation-driven biofuels platform, aligned with India's energy transition
goals and contributing meaningfully to global decarbonization efforts.
Financial Highlights:
Standalone:
The company's standalone financials also showed significant growth,
closely tracking the consolidated trend. Total income rose by 52.4%, reaching
Rs.1,94,070.60 lakhs compared to Rs.1,27,342.93 lakhs in the previous year. This
demonstrates strong revenue generation from core operations of the Company.
PBIDTAgrew by 46.5%, totalling Rs.35,778.32 lakhs, while Profit Before
Tax (PBT) saw an impressive 221.6% increase to Rs. 15,215.11 lakhs, showcasing improved
profitability.
The Net Profit After Tax (PAT) climbed 306.3% to Rs.14,061.53 lakhs,
underscoring a sharp improvement in the company's financial health. Additionally, EPS rose
from Rs.4.71 to Rs.20.08, reflecting greater shareholder value from standalone operations.
Consolidated:
Leafiniti Bioenergy Private Limited ("Leafiniti") continues
to be a wholly owned subsidiary of the Company during the financial year 2024-25.
Accordingly, the consolidated financial statements have been prepared for the year ended
March 31, 2025, including the financial results of Leafiniti. The consolidated financial
statements for the year ended March 31, 2025 is required from this financial year 2024 and
hence a comprehensive overview of the combined operational performance of both the Company
and Leafiniti is provided in this report.
During the period under review, the company delivered a robust
consolidated performance, marked by significant growth across all key financial metrics.
Total income rose by 53.8%, reaching Rs.1,96,852.78 lakhs compared to Rs.1,28,018.77 lakhs
in the previous year. This top-line expansion reflects strong demand and improved
operational execution across the Company.
PBIDTA (Profit Before Interest, Depreciation, Tax & Amortization)
increased by 51.1% to Rs.36,994.75 lakhs, indicating strong operating leverage. The
company's Profit Before Tax (PBT) more than tripled, growing by 255.3% to Rs. 15,944.28
lakhs, up from Rs.4,487.41 lakhs, highlighting improved cost efficiency and margin
expansion.
Net Profit After Tax (PAT) jumped 361% to T14,663.85
lakhs from Rs.3,180.79 lakhs, a clear indicator of the company's strengthened bottom line.
Correspondingly, Earnings Per Share (EPS) surged from Rs.4.25 to Rs.20.94,
reflecting enhanced value creation for shareholders.
2. Disclosures relating to Subsidiaries,
Associates and Joint Ventures:
The Company holds Leafiniti Bioenergy Private Limited
("Leafiniti") as its wholly owned subsidiary following the acquisition of 100%
equity stake in Leafiniti on February 24, 2024. In accordance with the provisions of
Section 136(1) of the Act, the Annual Report of the Company containing the standalone and
consolidated financial statements has been placed on the website of the Company, https://www.trualtbioenergy.com/investor-relations .
Further, the audited accounts of the Subsidiary Companies and the related detailed
information have also been placed on the website of the Company https://www.trualtbioenergy.com/investor-relations .
There has been no change in the business of the subsidiary during the
year under review. In accordance with Section 129(3) of the Act, the Company has prepared
consolidated financial statements of the Company and its Subsidiary Company, which forms
part of the Annual Report. A statement containing the salient features of the Financial
Statements of the Subsidiary Company is given in Form AOC-1 and annexed herewith as
Annexure -1 to this Report.
3. Amount if any, which the Board proposes to
transfer to any reserves:
Your Company has not transferred any amount to the reserves for the
period under review.
4. Dividend:
Ordinary Shares: The Board of Directors, after a thorough
evaluation of the Company's future expansion plans and other strategic considerations, has
decided not to recommend any dividend for the financial year 2024-25 to equity
shareholders. The Company has opted to retain the entire profit generated during this
period to fund strategic initiatives and support long-term growth objectives.
Preference Shares: For the financial year 2024-25, the Board has
made a provision for a preference dividend at the rate of 1.25% per annum, amounting to
Rs.51.42 lakhs, covering the period up to May 2, 2024the effective date of
conversion of the preference shares into equity. The said Dividend has been paid to all
eligible preference shareholders as on date of this report.
During the Financial Year 2024-25, the Company successfully completed
the conversion of all 4,69,19,000 Compulsorily Convertible Preference Shares (CCPS) of
Rs.100 each, carrying a 1.25% dividend, into 95,55,804 equity shares of Rs.10 each. The
conversion was executed at a price of Rs.491 per equity share, comprising a face value of
Rs.10 and a premium of Rs.481 per share. This transaction was completed with the unanimous
consent of all CCPS holders and was duly approved by the Board of Directors. Upon
completion of the conversion, all rights and obligations associated with the CCPS stood
automatically extinguished.
5. Change in the nature of Business:
There is no change in the nature of business during the period under
review.
6. Credit Rating:
During Fiscal Year 2024-25, the Company maintained a stable credit
profile as reflected by ratings assigned by Acuite Ratings 8 Research. Acuite had
initially assigned the Company a bank loan rating of ACUITE BBB (Stable) on August 11,
2023, followed by an issuer rating (IR) of ACUITE BBB (Stable) on September 29, 2023.
Further, on June 14, 2024, Acuite reaffirmed its issuer rating of ACUITE BBB (Stable) on
bank loans amounting to Rs. 1,634 Crores.
The credit ratings remained stable throughout Fiscal 2024-25,
underscoring the Company's consistent ability to meet its financial obligations and
maintain sound financial health.
Subsequently, in the current fiscal year 2025-26, the Company received
a rating letter dated May 08, 2025, from CRISIL assigning an issuer rating of A- (Stable)
for the bank facilities provided by State Bank of India, amounting to Rs. 538 Crores.
7. Material changes and commitments, if any,
affecting the financial position of the company, having occurred since the end of the Year
and till the date of the Report:
There have been no material changes and commitments, which affect the
financial position of the Company which have occurred between the end of the financial
year and the date of this Report.
8. Capital and Debt Structure:
The Authorized Share Capital of your Company as on March 31, 2025,
stands at Rs. 5,70,00,00,000/- (Rupees Five Flundred and Seventy Crore only) comprising
of:
Rs. 1,00,00,00,000/- (Rupees One Hundred Crore Only) divided into
10,00,00,000 (Ten Crore) Equity Shares of Rs. 10/- (Rupees Ten only) each; and
Rs. 4,70,00,00,000/- (Rupees Four Hundred and Seventy Crore Only)
divided into 4,70,00,000 (Four Crore Seventy Lakh) Preference Shares of Rs. 100/- (Rupees
Hundred Only) each.
a) Issue of shares or other convertible securities
The subscribed and paid-up share capital at the financial year ending
March 31, 2025 is as under:
Rs. 70,63,16,240/- (Rupees Seventy Crores Sixty-Three Lakhs Sixteen
Thousand Two Hundred Forty Only) divided into 7,06,31,624 (Seven Crore Six Lakh Thirty One
Thousand Six Hundred Twenty Four) Equity Shares of Rs. 10/- each, fully paid up.
Conversion of Compulsorily Convertible Preference
Shares (CCPS)
Pursuant to the approval of the Board of Directors at their meeting
held on May 03, 2024, 4,69,19,000 1.25% Compulsorily Convertible Preference Shares (CCPS)
of Rs.100/- each were converted into 95,55,804 Equity Shares of Rs. 10/- each, fully
paid-up, at a premium of Rs.481/- per share (conversion price of Rs.491/- per Equity
Share). The details of increase in the paid-up capital of the Company is as under:
Pre-conversion Paid-up Equity Capital |
Post Conversion Paid-up Equity Capital |
| Rs. 61,07,58,200/- (Rupees Sixty-One Crores
Seven Lakhs Fifty-Eight Thousand Two Hundred Only) divided into 6,10,75,820 Equity Shares
of Rs. 10f- each fully paid up. |
Rs. 70,63,16,240/- (Rupees Seventy Crores
Sixty-Three Lakhs Sixteen Thousand Two Hundred Forty Only) divided into 7,06,31,624 Equity
Shares of Rs. 10/- each, fully paid up. |
b) Issue of equity shares with differential rights
During the period under review, the Company has not issued equity
shares with differential rights.
c) Issue of Sweat Equity Shares
During the period under review, the Company has not issued any sweat
equity shares.
d) Details of Employee Stock Options
The Company does not have any Employee Stock Options and during the
period under review, the Company has not issued any Employee Stock Options.
e) Shares held in trust for the benefit of
employees where the voting rights are not exercised directly by the employees
During the period under review, the Company has not held the shares in
trust for the benefit of employees where the voting rights are not exercised directly by
the employees.
f) Issue of debentures, bonds or any
non-convertible securities
During the period under review, the Company has not issued any
debentures, bonds or any non-convertible instruments.
g) Issue of warrants
During the period under review, the Company has not issued any
warrants.
9. Investor Education and Protection Fund (IEPF):
There is no unpaid dividend amount or any other unclaimed instruments
lying with the Company and accordingly the Company need not to transfer any
amount/instruments to Investor Education and Protection Fund.
10. Directors and Key Managerial Personnel:
As on March 31, 2025, the Board of Directors consists of the following
Directors and Key Managerial Personnel:
| Name |
Designation |
| Mr. Vijaykumar Murugesh Nirani |
Managing Director |
| Mr. Vishal Nirani[N1] |
Whole-time Director |
| Mr. Durairaj Anand Murugan Jakkampati |
Executive Director |
| Mrs. Sushmitha Vijaykumar Nirani |
Non-Executive and Non-Independent Director |
| Mr. Chandrashekar Kanekal[N2] |
Non-Executive and Independent Director |
| Mr. Mallikarjun Bhimappa Dyaberi |
Non-Executive and Independent Director |
| Mr. Yagati Badarinarayana Ramakrishna[N3] |
Non-Executive and Independent Director |
| Mr. Anand Kishore |
Chief Financial Officer |
| Mr. Sudheer Sannapaneni[N4] |
Company Secretary & Compliance Officer |
[N1: Mr. Vishal Nirani is re-designated as Executive director effective
from the date of signing of this report]
[N2: Mr. Chandrashekar Kanekal tenure as Chairman ended on December 31,
2024]
[N3: Mr. Yagati Badarinarayana Ramakrishna has been designated as
Chairman of the Board effective May 13, 2025]
[N4: Mr. Sudheer Sannapaneni has resigned from post of Company
Secretary and Compliance officer effective from close of business hours on May 31,2025]
Retirement by rotation:
As per section 152 (6) of Companies Act, 2013 and rules made
thereunder, Mr. Durairaj Anand Murugan Jakkampati (DIN: 10411449) Director will retire by
rotation at the ensuing Annual General Meeting and being eligible offers himself for
reappointment. Based on the recommendation of the Nomination and remuneration Committee,
the Board considers his appointment.
Change in Board/Senior Management/Key Managerial
Personnel:
During the Financial Year 2024-25, the following changes took place in
the composition of the Board of Directors and Key Managerial Personnel (KMPs) of the
Company:
| Name |
Status |
Non-Executive Chairman and Independent
Director |
|
| Vishal Nirani (DIN:08434032) |
Appointed as the Whole Time Director of our
Company effective from April 1, 2024, following resolutions passed by our Board of
Directors in their meeting on March 21, 2024, and by our Shareholders at the Extraordinary
General Meeting (EGM) held on May 10, 2024. |
Changes in the Key Managerial Personnel
(KMP) |
|
| Dr. Debnath Mukhopadhyay Chief Financial
Officer (CFO) |
Resigned from the position of Chief Financial
Officer (CFO) vide email dated December 06, 2024 with effect from January 08, 2025 and the
same was taken note at the Board Meeting held on December 11, 2024 in accordance with
Provisions of Section 203 of the Companies Act, 2013. |
| Mr. Anand Kishore (CFO) |
Based on the recommendation of the Nomination
and Remuneration Committee, the Board appointed Mr. Anand Kishore as Chief Financial
Officer (CFO) of the Company with effect from February 19, 2025 and respective consents
for the same has received from him. |
| Mr. Mohith Kumar Khandelwal Co m pa ny Sec
reta ry (K M P) |
Based on the recommendation of the Nomination
and Remuneration Committee, the Board appointed Mr. Mohith Kumar Khandelwal as Company
Secretary & Compliance Officer of the Company effective from 22nd July 2024. |
|
Resigned from the position of Company
Secretary & Compliance Officer with effect from August 13, 2024 and the same was taken
note at the Board Meeting held on August 13, 2024 in accordance with Provisions of Section
203 of the Companies Act, 2013 |
| Mr. Sannapaneni Sudheer Company Secretary
(KMP) |
Mr. Sannapaneni Sudheer resigned from the
office of Company Secretary & Compliance Officer effective from 22nd July 2024. |
|
Based on the recommendation of the Nomination
and Remuneration Committee, the Board appointed Mr. Sannapaneni Sudheer as Company
Secretary & Compliance Officer of the Company effective from August 13, 2024. |
11. Meetings
A. Number of Board Meetings:
The Board meets at regular intervals to discuss and decide on business
strategies/policies and review the Company's financial performance. During the year under
review, the Board of Directors held 07 (Seven) meetings, each conducted with proper
notices issued and proceedings meticulously recorded and authenticated in the Minutes book
maintained for this purpose. The intervals between consecutive meetings adhered to the
stipulated periods outlined in the Companies Act, 2013. Below are the specific dates on
which these Board meetings took place:
| number Date of Meeting |
Number |
Date of Meeting |
| 1) 03-05-2024 |
5 |
16-08-2024 |
| 2) 22-07-2024 |
6 |
11-12-2024 |
| 3) 03-08-2024 |
7 |
19-02-2025 |
| 4) 13-08-2024 |
- |
- |
B. Attendance in the Board Meetings:
Name of the Director |
Category |
Number of Board meetings held |
No. of Meetings in which Directors are
entitled to attend |
No. of Meetings attended |
Whether attended last AGM |
| Mr. Vijaykumar Murugesh Nirani |
Managing Director |
7 |
7 |
7 |
Yes |
| Mr. Vishal Nirani |
Whole time Director |
7 |
7 |
7 |
Yes |
| Mrs. Sushmitha Vijaykumar Nirani |
Director |
7 |
7 |
6 |
Yes |
| Mr.Chandrasekhar Kanekal |
Independent Director |
7 |
7 |
7 |
Yes |
| Mr. Anand Murugan Jakkampati Durairaj |
Director |
7 |
7 |
3 |
Yes |
| Mr. Mallikarjun Bhimappa Dyaberi |
Independent Director |
7 |
7 |
7 |
Yes |
| Mr. Yagati Badarinarayana Ramakrishna |
Independent Director |
7 |
7 |
7 |
No |
C. Committees of our Board:
During the financial year the Company has constituted various
committees of the Board and the constitution of the Board Committees is in accordance with
the applicable provisions, if any, of the Companies Act, 2013, and the Articles of
Association of the Company and the Securities and Exchange Board of India (Listing
Obligations and Disclosure Requirements) Regulations, 2015.
The Board had 6 (Six) Committees viz.,
(i) Audit Committee
(ii) Nomination and Remuneration Committee (NRC)
(iii) Stakeholder Relationship Committee (SRC)
(iv) Corporate Social Responsibility Committee (CSR)
(v) Risk Management Committee (RMC)
(vi) IPO Committee
The Company's procedures for Board meetings extend to Committee
Meetings. Minutes of Committee proceedings are circulated to members and presented at
Board Meetings for review. All Committees comply with the composition and terms of
reference requirements under the Companies Act, 2013. Outlined below the composition of
Committees of the Board Committees:
Audit Committee: The Audit Committee was initially constituted and
approved its terms of reference on December 06, 2023. During the year under review, the
Audit Committee convened 6 (six) meetings, on May 03, 2024, July 22, 2024, August 03,
2024, August 16, 2024, December 11, 2024 and February 19, 2025.
Composition of Audit Committee and Attendance is mentioned below:
| Name of Members |
Position |
No. of meetings eligible to attend |
No. of meetings attended |
| Chandrasekhar Kanekal |
Chairman |
6 |
6 |
| Mallikarjun Bhimappa Dyaberi |
Member |
6 |
6 |
| Vi jay ku mar Murugesh Nirani |
Member |
6 |
6 |
Nomination and Remuneration Committee (NRC): The Nomination and
Remuneration Committee was initially constituted and approved its terms of reference on
December 06, 2023. During the year under review, the NRC convened 4 (four) meetings, on
July 22, 2024, August 13, 2024, December 11, 2024 and February 19, 2025.
Composition of NRC and Attendance is mentioned below:
Name of Members |
Position |
No. of meetings eligible to attend |
No. of meetings attended |
| Mallikarjun Bhimappa Dyaberi |
Chairman |
4 |
4 |
| Chandrasekhar Kanekal |
Member |
4 |
4 |
| Sushmitha Vijaykumar Nirani |
Member |
4 |
4 |
Stakeholder Relationship Committee (SRC): The Stakeholder
Relationship Committee (SRC) was initially constituted and approved its terms of reference
on December 06, 2023. During the year under review, the SRC convened 3 (Three) meetings,
on May 03, 2024, July 22, 2024 and August 13, 2024.
Composition of SRC and Attendance is mentioned below:
Name of Members |
Position |
No. of meetings eligible to attend |
No. of meetings attended |
| Chandrasekhar Kanekal |
Chairman |
3 |
3 |
| Mallikarjun Bhimappa Dyaberi |
Member |
3 |
3 |
| Anand Murugan Jakkampati Dural raj |
Member |
3 |
3 |
Corporate Social Responsibility Committee (CSR): The Corporate
Social Responsibility Committee (CSR) was initially constituted and approved its terms of
reference on December 06, 2023. During the year under review, the CSR Committee convened
two meetings, on July 22, 2024, and August 03, 2024.
Composition of CSR and Attendance is mentioned below:
Name of Members |
Position |
No. of meetings eligible to attend |
No. of meetings attended |
| Sushmitha Vijaykumar Nirani |
Chairperson |
2 |
2 |
| Mallikarjun Bhimappa Dyaberi |
Member |
2 |
2 |
| Vijaykumar Murugesh Nirani |
Member |
2 |
2 |
Risk Management Committee: The Risk Management Committee was
constituted by the Board of Directors and approved its terms of reference on February 19,
2025. During the year under review, the Committee did not convene any meeting.
Composition of Risk Management Committee and Attendance is
mentioned below:
ELLSPACING=?0? BORDER=?0? WIDTH=?100%? cellpadding=?2?>
Name of Members |
Position |
No. of meetings eligible to attend |
No. of meetings attended |
| Vijaykumar Murugesh Nirani |
Chairman |
NA |
NA |
| Vishal Nirani |
Member |
NA |
NA |
| Chandrasekhar Kanekal |
Member |
NA |
NA |
Initial Public Offering Committee (IPO) Committee: The IPO
Committee was constituted by the Board of Directors and approved its terms of reference on
January 13, 2024. During the year under review, the IPO Committee convened (1) One
meeting, on May 03, 2024.
Composition of IPO Committee and Attendance is mentioned below:
Composition of CSR and Attendance is mentioned below:
Name of Members |
Position |
No. of meetings eligible to attend |
No. of meetings attended |
| Vijaykumar Murugesh Nirani |
Chairperson |
1 |
1 |
| Vishal Nirani |
Member |
1 |
1 |
| Chandrasekhar Kanekai |
Member |
1 |
1 |
D. Number of General Meetings:
During the Financial Year ended March 31, 2024, 2 (Two) General
Meetings were held on the dates as listed below:
Number General Meeting Date |
General Meeting type |
| 1. 10/05/2024 |
Extra Ordinary General Meeting (EGM) |
| 2. 10/08/2024 |
Annual General Meeting (AGM) |
12. Particulars of Employees:
The disclosure as per provisions of Section 197 of the Companies Act,
2013 read with Companies (Appointment and Remuneration of Managerial Personnel) Rules,
2014, in respect of employees of your Company, is available for inspection by the
Shareholders at the Corporate Office of the Company, during the business hours i.e.,
between 10.00 AM (1ST) to 05.00 PM (1ST), on all working days (i.e., except Saturdays,
Sundays and Public Holidays), upto date of the ensuing 4th (Fourth) Annual General Meeting
of the Company, subject to such restrictions as may be imposed by the Government(s) and /
or local authority(ies) from time to time. If any shareholder is interested in inspecting
the records thereof, such Shareholder may write to cs@trualtbioenergy.com .
13. Policy on Appointment and Remuneration:
The guiding Policy on remuneration of Directors, Key Managerial
Personnel and employees of the Company is as under:
Remuneration to Key Managerial Personnel, Senior Executives,
Managers, Staff and Workmen commensurate with the industry standards in which it is
operating taking into account the performance leverage and factors so as to attract and
retain talent.
For Directors, it is based on the Shareholders' approval,
provisions of the Companies Act, 2013 and Rules framed therein, circulars, guidelines
issued by the Central Government and other authorities from time to time.
In addition to the above, the Board, on the recommendation of the
Nomination and Remuneration Committee, has framed the policy for selection and appointment
of Directors including determining qualifications and independence of a Director, Key
Managerial Personnel ("KMP"), Senior Management Personnel and their remuneration
as part of its charter and other matters provided under Section 178(3) of the Companies
Act, 2013.
Pursuant to Section 134(3) of the Companies Act, 2013, the Nomination
and Remuneration policy of the Company which lays down the criteria for determining
qualifications, competencies, positive attributes and independence for appointment of
Directors and policies of the Company relating to remuneration of Directors, KMP and other
employees is available on the Company's website at https://www.trualtbioenergy.com/investor-relations .
We affirm that the remuneration paid to Directors, Senior Management and other employees
is in accordance with the remuneration policy of the Company.
14. Board Evaluation:
As per the provision of Section 134(3) (p) of the Companies Act, 2013,
the Company has devised a policy for performance evaluation of the individual Directors
and the Board, which includes criteria for performance evaluation.
The Board's performance was evaluated based on inputs received from all
the Directors, taking into account criteria such as the composition and structure of the
Board, its effectiveness, performance, processes, and information provided to the Board,
among others.
15. Internal Financial Controls:
Your Company adopted policies and procedures which enables
implementation of appropriate Internal Financial Controls across the organisation and also
ensures the orderly and efficient conduct of business, including adherence to the
Company's Policies, safeguarding of its assets, the prevention and detection of frauds and
errors, the accuracy and completeness of the accounting records, and timely preparation of
reliable financial disclosures. Internal Financial Controls are an integral part of the
Risk Management Process, addressing financial and financial reporting risks.
M/s BDO India LLP has submitted to the Board, the report on Internal
Financial Controls (IFC) and the Risk Control Matrix (RCM) for the financial year 2024-25.
The same was noted by the Board.
The testing covered key controls across various financial and
operational processes. The report arising from this testing has been completed and
reviewed. It outlines the effectiveness of the controls in place and confirms their
operating effectiveness across the identified processes.
16. Directors' Responsibility Statement:
Based on the framework of internal financial controls and compliance
systems established and maintained by the Company, work performed by the Internal,
Statutory Auditors and the reviews performed by Management and the Board, the Board is of
the opinion that the Company's internal financial controls were adequate and effective
during financial year.
Accordingly, pursuant to Section 134 (3) (c) and 134 (5) of the
Companies Act, 2013, the Board of Directors, to the best of their knowledge and ability,
confirm that:
i. In preparation of the annual accounts, the applicable accounting
standards had been followed along with proper explanation relating to material departures.
ii. The directors have selected such accounting policies and applied
them consistently and made judgments and estimates that are reasonable and prudent so as
to give a true and fair view of the state of affairs of the company at the end of the
financial year and of the profit of the company for that period.
iii. The directors have taken proper and sufficient care for the
maintenance of adequate accounting records in accordance with the provisions of this Act
for safeguarding the assets of the company and for preventing and detecting fraud and
other irregularities.
iv. The directors have prepared the annual accounts on a going concern;
and
v. The directors have laid down internal financial controls to be
followed by the company and that such internal financial controls are adequate and were
operating effectively.
vi. The directors have devised proper systems to ensure compliance with
the provisions of all applicable laws and that such systems were adequate and operating
effectively.
17. Declaration by Independent Directors:
The Company has received declarations from all the Independent
Directors confirming that they meet the criteria of independence as prescribed under
sub-section (6) of Section 149 of the Companies Act, 2013. There has been no change in the
circumstances affecting their existing status as independent directors of your Company.
In compliance with Schedule IV to the Companies Act, 2013 the
Independent Directors held their meeting on March 27,2025 without the presence of
non-independent directors and members of the management, inter alia, to discuss the
following:
Report of performance evaluation of the Board from the Chairman
of the Board.
Review of the performance of non-independent directors and the
Board.
Review of the performance of the Chairman of the Company; and
Assessment of the quality, quantity and timeliness of flow of
information to the Board.
18. Familiarization Program for the Independent
Directors:
The Company has established a comprehensive Familiarization Program for
its Independent Directors. This program is designed to provide them with insights into
their roles, rights, responsibilities under the Companies Act, 2013, and the Company's
business operations, including its business model, product and service offerings,
competitive landscape, and industry-specific risks and opportunities.
The program also familiarizes Independent Directors with the Company's
Board procedures, Committee structures, and enables effective participation in Board and
Committee meetings. Additionally, interactive sessions are conducted during Board meetings
to keep the Directors abreast of legal and regulatory developments relevant to the
Company.
This program prepares Directors to actively contribute to strategic
decisions and governance within the company. The details of the familiarization programmes
are available on the website of the Company at https://www.trualtbioenergy.com/investor-relations
19. Policy on Board Diversity:
The Board, upon recommendation of the Nomination and Remuneration
Committee, has adopted a Board Diversity Policy which sets the criterion for appointment
as well as continuance of Directors, at the time of re-appointment of Director in the
Company. As per the policy, the Board has an optimum combination of members with
appropriate balance of skill, experience, background, gender and other qualities of
Directors required by the Directors for the effective functioning of the Board.
The Board of Directors is responsible for review of the policy from
time to time. Policy on Board Diversity has been placed on the Company's website at https://www.trualtbioenergy.com/investor-relations
20. Statutory Auditor and Report:
M/s. N.M. Raiji & Company (FRN: 108296W), Chartered Accountants,
Mumbai, have been appointed by the Shareholders as the Statutory Auditors of the Company
to hold office for a period of 5 (Five) consecutive years i.e., with effect from the
conclusion of the 2nd (Second) Annual General Meeting until the conclusion of the 7th
(Seventh) Annual General Meeting pursuant to the provisions of Section 139 of the
Companies Act, 2013. The Statutory Auditors have confirmed that they are not disqualified
from continuing as Auditors of the Company.
The observations of the Auditors in their report are self-explanatory
and therefore, in the opinion of the Directors, do not call for further comments. During
the Financial Year under review, there are no qualifications, adverse remarks or
disclaimers made by the Statutory Auditor on the financial statements of the Company and
therefore, do not call for any further explanation or comments from the Board under
Section 134 (3) of the Companies Act, 2013.
21. Frauds reported by the Auditor:
During the year under review the Statutory Auditors have not reported
any instances of frauds committed in the Company by its Directors, officers or employees
under section 143 (12) of the Companies Act 2013.
22. Internal Auditor and Report:
M/s ZADN & Associates LLP, Chartered Accountants, have been
appointed as the Internal Auditors of the Company in accordance with Section 138 of the
Companies Act, 2013, along with Rule 13(1) of the Companies (Accounts) Rules, 2014, and
Rule 8 of the Companies (Meetings of Board and its Powers) Rules, 2014. Their mandate
includes ensuring compliance with relevant laws and regulations and evaluating the
adequacy of the Company's internal control systems for the Financial Year 2024-25. They
have diligently provided their reports on a quarterly basis, thereby contributing to
continuous monitoring and enhancement of internal controls.
The term of Internal Auditors of the Company, M/s. ZADN &
Associates LLP, Chartered Accountants, Mumbai, was up to the end of the financial year
2024-25. Since their term has expired, it is required for the Company to appoint an
Internal Auditor for the financial year 2025-26. Based on the recommendation of the Audit
Committee, the Board re-appointed M/s. ZADN & Associates LLP, Chartered Accountants,
Mumbai, at such remuneration as recommended by the Audit Committee and approved by the
Board.
23. Secretarial Auditor and Report:
Pursuant to the provisions of Section 204 of the Companies Act, 2013
and the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014, M/s
S.P. Ghali & Co, Company Secretaries have been appointed as Secretarial Auditors to
conduct Secretarial Audit for the FY ended March 31, 2025.
During the financial year under review there are no qualifications,
adverse remarks or disclaimers made by the Secretarial Auditor in his Secretarial Audit
Report. The Secretarial Audit Report is annexed herewith as Annexure - II.
24. Cost Auditor and Report:
As per Section 148 of the Companies Act, 2013 and the Companies (Cost
Records and Audit) Rules, 2014, the Company is mandated to maintain cost accounts and
records for its various manufacturing activities, which are subject to audit.
Upon the recommendation of the Audit Committee, the Board has appointed
M/s. R. Nanabhoy & Co., Cost Accountants, to audit the cost accounts related to the
Company's products for the Financial Year 2025-26.
25. Compliance with Secretarial Standards:
The Company has devised proper systems to ensure compliance with the
provisions of all applicable Secretarial Standards issued by the Institute of Company
Secretaries of India and that such systems are adequate and operating efficiently.
26. Details of Deposits:
During the financial year under review the Company has not accepted any
deposits falling within the meaning of Section 73 of Companies Act, 2013 read with the
Companies (Acceptance of Deposits) Rules, 2014. Further, there are no amounts outstanding
at the beginning of financial year 2024-25, which can be classified as 'Deposits' in terms
of Section 73 of the Companies Act, 2013 read with Companies (Acceptance of Deposit)
Rules, 2014.
27. Particulars of Loans, Guarantees and
Investments:
During the financial year under review the details of loans given or
guarantees provided to various parties are detailed in the Annexure-lll to the Report.
Details of Past Loans, Guarantees and Investments if any, covered under
the provisions of Section 186 and Section 185 of the Companies Act, 2013 and any other
applicable provisions are available under notes to accounts, attached to the Standalone
Financial Statements. The full particulars are available in the Register maintained under
Section 186 of the Act, which is available for inspection during business hours on all
working days (except Saturday and Sunday) at the corporate office of the Company.
28. Particulars of Contracts or Arrangements with
Related Parties:
There are no materially significant related party transactions made by
the Company which may have potential conflict with interest of the Company at large.
During the Financial Year, the Company has not entered into contracts/ arrangements/
transactions with the related parties which could be considered material in accordance
with the Company's 'Policy on Materiality' of Related Party Transactions and Dealing with
Related Party Transactions'. The said policy is available on the website at https://www.trualtbioenergy.com/investor-relations .
All the contracts/arrangements/transactions entered into by the Company with the related
parties during the financial year 2024-25, were in the ordinary course of business and on
an arm's length basis.
In accordance with section 134(3)(h) of the Act, read with rule 8(2) of
the Companies (Accounts) Rules, 2014, and in accordance with Indian Accounting Standards
24, the related party transactions entered by the Company during the financial year are
disclosed in Annexure - IV in Form AOC-2, which forms part of this report and is
disclosed under notes to financial statements.
Prior approval of the Audit Committee was obtained for all the related
party transactions for the Financial year 2025-26 at its meeting held on May 13,2025.
Further, prior omnibus approval of the Audit Committee is obtained on a yearly basis for
the transactions which are of a foreseen and repetitive nature. The transactions entered
pursuant to the omnibus approval so granted are audited and a statement giving details of
all related party transactions is placed before the Audit Committee for its approval, on a
regular basis. The policy on Related Party Transactions as approved by the Board has been
uploaded on the Company's website at https://www.trualtbioenergy.com/investor-relations .
None of the Directors has any pecuniary relationships or transactions vis-a-vis the
Company except to the extent of their shareholding and directorship status.
29. Corporate Social Responsibility (CSR):
In terms of the provisions of section 135 of the Companies Act, 2013,
read with Companies (Corporate Social Responsibility Policy) Rules, 2014, the Board of
Directors of the Company has constituted a Corporate Social Responsibility
("CSR") Committee. The Committee recommends to the Board activities as specified
in Schedule VII of the Companies Act, 2013 to be undertaken during the year. The
composition and terms of reference of the CSR Committee are approved by the Board.
The Company has a dedicated CSR Policy, which can be accessed on its
website (https://www.trualtbioenergy.com/governance-investor ),
with a focus on enhancing local community development and promoting sustainable
livelihoods. Key initiatives include organizing health camps and awareness programs in
collaboration with local hospitals, empowering youth through skill development, supporting
women's empowerment initiatives, nurturing future leaders through educational programs,
fiscal year 2024-25, the Company allocated Rs.65.45 Lakhs towards CSR activities,
specifically targeting projects aligned with Schedule VII of the Companies Act 2013
through implementing agencies. The Corporate Social Responsibility Report in the required
format is provided as Annexure - V to this report.
30. Conservation of Energy, Technology
Absorption, Foreign Exchange Earnings and Outgo:
The Company is engaged in the business of Production, Processing of
Bio-Diesel, Ethanol and Compressed Biogas (CBG). Information with respect to conservation
of energy, technology absorption, foreign exchange earnings and outgo pursuant to Section
134(3)(m) of the Act read with the Companies (Accounts) Rules, 2014 is prepared and the
same is enclosed as Annexure - VI to this Report.
31. Risk Management:
Our Company has implemented a comprehensive Risk Management Policy in
alignment with the Companies Act, 2013, to systematically identify, assess, and mitigate a
wide spectrum of risks affecting its operations. Endorsed by the Board of Directors, this
policy integrates robust risk management practices across all facets of the organization.
It encompasses strategies to manage asset and property risks, personnel risks, business
risks such as market volatility and regulatory changes, credit risks, geographical risks,
operational risks including supply chain disruptions and technological failures, legal
risks, environmental health and safety risks, economic environment risks, and
cybersecurity risks.
The policy emphasizes proactive risk identification and mitigation
through structured processes, regular evaluations, and strategic initiatives. It mandates
the allocation of necessary resources and responsibilities to ensure effective risk
management at all levels of the company. By adhering to stringent compliance measures,
continuous monitoring, and adaptive strategies, Our Company main aims to enhance
operational resilience, maintain regulatory compliance, and capitalize on growth
opportunities amidst a dynamic and challenging business environment.
Brief details of risks and concerns are given in the Management
Discussion and Analysis Report, which forms part of this Annual Report.
32. Vigil Mechanism:
In accordance with the provisions of Section 177(9) & (10) of the
Companies Act, 2013 and other applicable provisions, a Vigil Mechanism has been
established by the Company to enable directors and employees to report genuine concerns
without fear of reprisal. This mechanism, also known as the whistle blower policy, aims to
address issues related to leakage of unpublished price sensitive information (UPSI),
illegal activities, and unethical behaviour within the organization.
The whistle-blower policy outlines a structured framework and process
for reporting concerns or grievances to the Chairman of the Audit Committee. It ensures
confidentiality and protection for whistle-blowers, encouraging them to disclose
information that could impact the Company's integrity or operations adversely.
During the current reporting period, the status of concerns or
complaints reported under the vigil mechanism is as follows:
Total number of concerns/complaints received: Nil
* Nature of concerns/complaints: Nil
Action taken: Not Applicable
* Resolutions and outcomes: Not Applicable.
The detailed report on the status of concerns or complaints can be
accessed in the Annual Report or through the Company's official website at the provided
link: https://www.trualtbioenergy.com/investor-relations .
This transparency underscores the Company's commitment to ethical governance and
accountability in addressing internal issues effectively.
33. Material Orders of Judicial Bodies
/Regulators:
No significant and material orders were passed by the regulators or
court or tribunals impacting the going concern status and Company's operations in future.
34. Annual Return:
Pursuant to Section 92(3) and Section 134(3) (a) of the Companies Act,
2013, the Annual Return of the Company is placed on its website at https://www.trualtbioenergy.com/investor-relations .
By virtue of amendment to Section 92(3) of the Companies Act, 2013, the Company is not
required to provide extract of Annual Return (Form MGT-9) as part of the Board's report.
35. Human Resources:
For the Company, fostering a strong work culture is a top priority,
backed by solid HR systems and development initiatives. While changes in operations may
affect employee numbers, the company is committed to maintaining an agile,
high-performance, and diverse workplace. With a strong emphasis on values like innovation,
customer focus, and sustainability, the company enhances customer relationships through
the collective skills and dedication of its workforce, making it a preferred employer. The
company consistently fosters harmonious industrial relations across its facilities,
ensuring continuous operational excellence.
Our company employs a diverse workforce across various departments and
locations. These departments include Accounts, Administration, Civil, Co-Generation,
Effluent Treatment Plant, Electrical, Environment, HR, Instrumentation, Industrial
Relations (IR), Mechanical, Welding, Production, Process, Quality Assurance and Quality
Control, Research and Development (R&D), Purchase, Security, Sales, Stores, and Water
Treatment Plant. Additionally, we engage independent contractors who oversee on-site
contract labor for specific ancillary operations. Our operations have been free from major
work stoppages due to labor disputes or work cessation. Our attrition rates reflect stable
employee retention efforts during these periods.
36. Health, Safety and Security Measures:
Ensuring the safety and well-being of our workforce is paramount at our
Company. We maintain stringent health, safety, and security measures across all our
facilities. As responsible corporate citizens, we prioritize human health and safety,
strictly adhering to Occupational Health and Safety management standards. This commitment
is ingrained in our daily operations, integrating responsibilities for occupational
health, hygiene, and safety seamlessly. Regular safety inspections and audits are
conducted at all plants and project sites to uphold these standards. Furthermore, we
actively promote health and safety awareness through programs across our locations,
fostering a culture of well-being among our employees.
The Company places utmost importance on the safety and well-being of
its employees. Through proactive implementation of precautionary measures and rigorous
safety protocols, we demonstrate our unwavering commitment to protecting our workforce
from potential risks. By consistently enforcing preventive safeguards at all our plants
and sites, we ensure a secure and safe work environment for everyone.
37. Code of Conduct:
Board of Directors have adopted the Code of Business Conduct and Ethics
(the 'Code of Conduct'), which applies to all Directors, Officers and Employees of
Company. The Code of Conduct reflects the commitment to doing business with integrity and
in full compliance with the law and provides a general roadmap for all the Directors,
Officers and Employees to follow as they perform their day-to-day responsibilities with
the highest ethical standards. The Code of Conduct also ensures that all members perform
their duties in compliance with applicable laws and in a manner that is respectful of each
other.
38. Disclosure under "The Sexual Harassment of Women at the
Workplace (Prevention, Prohibition and Redressal) Act 2013":
The Company has in place a Policy for Prevention Prohibition and
Punishment of Sexual Harassment of Women at Workplace in line with the requirements of the
Sexual Harassment of Women at the Workplace (Prevention, Prohibition and Redressal) Act
2013. Internal Complaints Committee has been set up to redress complaints received
regarding sexual harassment. All employees are covered under this policy. During the year
under review, there were no complaints filed pursuant to the Sexual Harassment of Women at
Workplace (Prevention, Prohibition and Redressal) Act, 2013. The details are as below:
SI. No. Particulars |
Status |
| 1 Number of complaints on sexual harassment
received |
Nil |
| 2 Number of complaints disposed off during
the year |
Not Applicable |
| 3 Number of cases pending for more than
ninety days |
Not Applicable |
| 4 Number of workshops or awareness programs
against sexual harassment carried out. |
The Company regularly conducts necessary
awareness programs for its employees. |
| 5 Nature of action taken by the employer or
district officer |
Not Applicable |
39. Key Policies of the Company:
The following key policies of the Company have been adopted or updated
in compliance with the applicable provisions of Indian laws. A list of these policies is
provided below:
Corporate Social Responsibility (CSR) Policy
Nomination & Remuneration Policy
Risk Management Policy
Related Party Transactions (RPT) Policy
Prevention of Sexual Harassment (POSH) Policy
Preservation of Documents Policy
Materiality Policy
Familiarization Programme for Independent Directors
Dividend Distribution Policy
Board Diversity Policy
Code of Conduct for the Board and Senior Management
Code of Conduct for Fair Disclosure of Unpublished Price
Sensitive Information (UPSI)
Policy for Determining the material subsidiaries.
Policy for succession plan for appointment of Directors and
Senior Management
Cybersecurity Policy
Anti money Laundering Policy
Anti Bribery and Anti-Corruption Policy
Vigil Mechanism/Whistle Blower Policy
Code of conduct to Regulate, Monitor and Report trading by
Designated Persons and Immediate Relatives of Designated Persons
40. Other Disclosures:
The Company did not revise its financial statements during the
fiscal year under review.
There were no applications made or proceedings pending against
the Company under the Insolvency and Bankruptcy Code, 2016, and this status remained
unchanged at the end of the financial year.
No valuations of the Company were conducted during the year for
One Time Settlement (OTS) purposes or for obtaining loans from banks/financial
institutions.
The Management Discussion and Analysis is prominently featured
in this Annual Report emphasizing our steadfast commitment to robust corporate governance
practices.
The abstract of the Business Responsibility and Sustainability
Report is being made part of the Annual report for the financial year 2024-25.
Compliance with Maternity Benefit Act, 1961: The Company has
complied with the applicable provisions of the Maternity Benefit Act, 1961, including
those relating to maternity leave, nursing breaks, and other prescribed benefits and
entitlements for employees. The Company remains committed to supporting the health and
well-being of its workforce in accordance with the law.
41. Acknowledgement:
Your directors place on record their gratitude to the Central
Government, various State Governments and Company's Bankers, advisors, business
associates, partners and vendors for the valuable advice, guidance, assistance,
cooperation, and encouragement they have extended to the Company from time to time. The
Directors also take this opportunity to thank the company's customers, suppliers, and
shareholders for their consistent support to the Company.
We place on record our appreciation for the contribution made by our
employees at all levels. Our consistent growth was made possible by their hard work,
solidarity, cooperation, and support.
| Date: 26/07/2025 |
Vijaykumar Murugesh Nirani |
For and on Behalf of the Board |
| Place: Bengaluru |
Managing Director |
Trualt Bioenergy Limited |
|
DIN: 07413777 |
Sushmitha Vijaykumar Nirani |
|
Address: Mudhol, Bagalkot, |
Director |
|
Karnataka, India 587313 |
DIN: 08356858 |
|
|
Address: Vijay Nagar, |
|
|
Kulali Cross, Mudhol |
|
|
Ward No 5, Bagalkot - 587313 |
|